Head to Head Survey: BioLife Solutions (BLFS) & Nexeon Medsystems (NXNN)

Nexeon Medsystems (NASDAQ: BLFS) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Insider and Institutional Ownership

27.8% of BioLife Solutions shares are owned by institutional investors. 61.2% of Nexeon Medsystems shares are owned by insiders. Comparatively, 38.5% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Nexeon Medsystems and BioLife Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexeon Medsystems -7.70% -40.39% -22.91%
BioLife Solutions 1.76% 2.24% 1.92%

Earnings & Valuation

This table compares Nexeon Medsystems and BioLife Solutions’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nexeon Medsystems $3.30 million 4.78 -$2.17 million ($3.64) -2.20
BioLife Solutions $11.02 million 35.79 -$2.51 million ($0.21) -114.10

Nexeon Medsystems has higher earnings, but lower revenue than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Nexeon Medsystems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Nexeon Medsystems and BioLife Solutions, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexeon Medsystems 0 1 0 0 2.00
BioLife Solutions 0 0 3 0 3.00

BioLife Solutions has a consensus price target of $17.67, suggesting a potential downside of 26.27%. Given BioLife Solutions’ stronger consensus rating and higher possible upside, analysts plainly believe BioLife Solutions is more favorable than Nexeon Medsystems.


BioLife Solutions beats Nexeon Medsystems on 10 of the 13 factors compared between the two stocks.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Receive News & Ratings for Nexeon Medsystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon Medsystems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply